newsfilter
← Earnings
Earnings Releases·

Pulmatrix — Third Quarter 2026 Earnings Summary

  • Total operating expenses rose to $1.2 million in Q3 2026 from $0.9 million in the prior year period, driven by merger-related activities, resulting in a net loss of $1.2 million ($0.34 per share) compared to $0.9 million ($0.24 per share) previously.
  • The company anticipates closing its merger with Eos SENOLYTIX by the end of 2026, with cash and cash equivalents of $1.4 million deemed sufficient to fund operations through the closing, subject to Nasdaq listing approval and a reverse stock split.
  • Strategic progress includes the completion of a $1.0 million private placement of Series B Convertible Preferred Stock with an Eos affiliate, the FDA acceptance of a Phase 2 IND for PUR3100, and approval to proceed to a Phase 3 trial for PUR1900 in India.
  • Clinical development remains on hold as the company seeks to license or monetize clinical assets, while iSPERSE™ technology continues to generate royalties from partners MannKind Corporation and Cipla.
Company
PULMATRIX INC
Sector
Healthcare
Industry
Biotechnology